Extending Treatment Intervals of R-CHOP Therapy Might Be Acceptable for Some Patients with Non-indolent Non-Hodgkin’s B-cell Lymphoma
| Autor: | Keigo, Fujishita, Sando, Yasuhisa, Satoshi, Oka, Yuka, Fujisawa, Takuya, Machida, Toshi, Imai |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Male
Antibiotics Antineoplastic Lymphoma B-Cell Antineoplastic Agents Hormonal R-CHOP therapy relative dose intensity Antineoplastic Agents Middle Aged Prognosis non-Hodgkin’s lymphoma Disease-Free Survival Antineoplastic Agents Immunological Doxorubicin Vincristine immune system diseases hemic and lymphatic diseases Antineoplastic Combined Chemotherapy Protocols Humans Prednisone Female Rituximab Cyclophosphamide Aged Retrospective Studies |
| Zdroj: | Acta Medica Okayama. 76(1):17-24 |
| ISSN: | 0386-300X |
| Popis: | R-CHOP therapy is generally performed every 3 weeks. We investigated the effects of extending the interval of R-CHOP therapy for > 1 week on the prognoses of patients with non-indolent non-Hodgkin’s B-cell lymphoma. Among the 338 patients with non-indolent non-Hodgkin’s B-cell lymphoma who received initial chemotherapy at our institution, we focused on 178 patients who received R-CHOP therapy and analyzed the outcomes of the patients stratified by the treatment intervals. The estimated 3-year overall survival (OS) for the entire population was 82.1%. Patients treated at intervals of ≥ 4 weeks were significantly older, and they had significantly longer follow-up periods and lower relative dose intensity. But the estimated 3-year OS was comparable to those treated at |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|